Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Syncona adds two oncology investments to portfolio
(Sharecast News) - Life science investor Syncona announced the addition of two new oncology companies to its portfolio on Thursday. The FTSE 250 company said the investments included leading an €80m (£68.4m) series-B financing round for iOnctura, and launching a new company, Yellowstone Biosciences, with a £16.5m series-A financing commitment.
Syncona said it had invested €30m in iOnctura, a European clinical-stage biopharmaceutical company focussed on developing therapies for neglected and hard-to-treat cancers.
The investment secured Syncona a 23% stake in the company.
iOnctura's leading candidate, roginolisib, was described as a first-in-class allosteric modulator of PI3K delta (PI3Kδ), showing promise in treating various solid and haematological cancers.
Roginolisib had demonstrated long-term safety and emerging efficacy in a phase 1b clinical trial for metastatic uveal melanoma, a rare eye cancer.
The company was planning to initiate phase two trials in 2024 for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis.
Syncona also announced the launch of Yellowstone, a new company dedicated to developing soluble bispecific T-cell receptor (TCR)-based therapies.
With a £16.5m series-A investment, Syncona held a 60.9% stake in Yellowstone.
The company would be focussed on creating a new class of cancer therapeutics by targeting specific, frequently-expressed peptide antigens derived from a biobank of adult acute myeloid leukaemia (AML) patients.
Syncona said that approach aimed to selectively kill cancer cells, potentially transforming treatment for AML and other cancers.
Yellowstone was spun out from the University of Oxford, and was supported by Oxford University Innovation (OUI).
The company was led by professor Paresh Vyas, a renowned academic clinician, and Neil Johnston, who would bring extensive industry experience from his tenure at Novartis.
Syncona representatives, including SIML chief executive officer Chris Hollowood and investment partner Gonzalo Garcia, would join the Yellowstone board.
"iOnctura represents a compelling opportunity to invest in line with our strategy and capital allocation focus in a clinical-stage company, and take a promising lead programme through to late-stage development," said Roel Bulthuis, managing partner and head of investments at Syncona Investment Management, and iOnctura board member.
"To date, no company has been able to successfully target this well-known cancer pathway with sufficient precision."
Bulthuis said that by "allosterically modulating" PI3Kδ, iOnctura had achieved a new level of precision and could be the first company to develop a clinically-meaningful medicine targeting the pathway.
"Its programmes have potential utility across a range of cancers, which we are supporting the company to unlock through a refined clinical strategy."
At 1106 BST, shares in Syncona were down 0.46% at 113.07p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.